Even though a key component of the law will not go into impact until January 2015.

, a specialty pharmaceutical company focused on the advancement and commercialization of innovative therapies for the treating acute and breakthrough pain, today announced that top-collection data from its previously announced open-label, active-comparator research of its lead item applicant, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Culture of Anesthesiologists PostGraduate Assembly conference in New York City to be kept December 14-18, 2012.Abramson is certainly internationally known for basic science and clinical research in neuro-scientific arthritis and inflammation, and has published a lot more than 200 papers in peer reviewed journals including Character, Science, Cartilage and Osteoarthritis, Clinical Rheumatology and Annals of Rheumatic Diseases. He’s a co-editor of the journal Arthritis & Rheumatism, a former person in the Rheumatology Plank of the American Board of Internal Medicine , immediate past president of the Osteoarthritis Research Culture International and previous chairman of the Arthritis Advisory Committee of the Food and Medication Administration . Dr. Abramson was appointed by the American University of Rheumatology plank of directors as the 1st chair of the ACR-FDA Medication Safety Committee.